Maxime Dely: The Vital Role of Plasma-Derived Clotting Factors in Rare Disease Care
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:
”Clotting factors: when plasma becomes a life-saving medicine
Plasma-derived medicinal products (PDMPs), such as factor VIII or IX concentrates, remain essential for patients living with rare and severe bleeding disorders
Conditions treated:
- Hemophilia A and B (factor VIII or IX deficiency)
- Rare congenital deficiencies (factor V, XI, XIII, protein S, plasminogen…)
- Severe coagulation disorders linked to liver disease, trauma, or critical care situations
Across the world, millions of patients rely every year on plasma-derived medicines when recombinant alternatives are not yet available, effective, or well tolerated.
In many cases, these treatments are the only therapeutic option capable of preventing life-threatening bleeding and enabling a normal quality of life.
Behind every vial of medicine lies a plasma donation — transformed into treatment, hope, and survival for patients facing rare diseases.
How can we raise greater awareness of the vital role that plasma-derived coagulation factors play in rare disease care and innovation?”
Stay updated on the emerging in transfusion medicine with Hemostasis Today.
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 13, 2025, 09:54Cihan Ay: ISTH 2026 In Planning!
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 11, 2025, 15:42The True Price of Gene Therapy: Breaking Down Beqvez’s $3.5M Cost and What Really Drives It
-
Sep 13, 2025, 10:36Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
-
Sep 13, 2025, 09:44Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
-
Sep 13, 2025, 01:37Flora Peyvandi on Iron Deficiency in Mild to Moderate Bleeding Disorders
-
Sep 12, 2025, 07:28Lauren Murphy: Platelets as DNA “Sponges”
-
Sep 12, 2025, 03:38Haematologica Early View: Omid Seidizadeh Explores Genetics Behind Clinical Variability in Type 2 VWD
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 12, 2025, 07:54Aurelio Maggio Thanks Contributors to Webinar on Advanced Treatments in Rare Blood Disorders
-
Sep 12, 2025, 07:20Women for Their Health: Paige Bingham on Boston Scientific's Initiative ''Close the Gap'' Act During AFib Awareness Month
-
Sep 11, 2025, 15:27Postpartum Haemorrhage: In Kenya, More than 120 Mothers Die for Every 100,000 Live Births